# Dexmedetomidine’s Role in Adult ICU After 20 Years of Experience—A Narrative Review

## TL;DR

This review summarizes how Dexmedetomidine, a drug used in ICU settings, improves patient outcomes by reducing sedation time and preventing delirium, especially in elderly patients.

## Contribution

The paper highlights Dexmedetomidine's expanded role beyond sedation, emphasizing its neuroprotective and anti-inflammatory effects in ICU patients.

## Key findings

- Dexmedetomidine reduces intubation duration and ICU length of stay.
- It enhances sleep quality and prevents ICU delirium and post-ICU syndrome.
- Emerging evidence suggests neuro-, renal-, and cardio-protective effects of Dexmedetomidine.

## Abstract

What are the main findings?
The unique arousable sedation in combination with mild opioid-spare analgesic effects, has confirmed to effectively minimize duration of intubation and mechanical ventilation, ICU and hospital length of stay the total hospital stay cost.The anxiolytic and sympatholytic action have proved to sufficiently enhance sleep qualit, and has an important role on prevention and treatment of ICU delirium and post-ICU syndrome, especially among elderly patients.

The unique arousable sedation in combination with mild opioid-spare analgesic effects, has confirmed to effectively minimize duration of intubation and mechanical ventilation, ICU and hospital length of stay the total hospital stay cost.

The anxiolytic and sympatholytic action have proved to sufficiently enhance sleep qualit, and has an important role on prevention and treatment of ICU delirium and post-ICU syndrome, especially among elderly patients.

What is the implication of the main finding?
Increasingly evident advocate promising neuro-, renal-, and cardio-protective and anti-inflammatory effects of Dex, which are attributed to autophagy and apoptosis inhibition, sympatholytic, and ischemia/reperfusion (I/R) injury protective effect.

Increasingly evident advocate promising neuro-, renal-, and cardio-protective and anti-inflammatory effects of Dex, which are attributed to autophagy and apoptosis inhibition, sympatholytic, and ischemia/reperfusion (I/R) injury protective effect.

Background: Dexmedetomidine (Dex) is a well-known a2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic effects that has been used principally as adjuvant sedation in the ICU. The enhanced clinical experience of Dex’s use and its physiological effects encourage its application beyond the initial indications. Aim: The purpose of this review is to summarize the current knowledge of Dex’s recently expanded applications in critically ill intensive care unit (ICU) adult patients. Methods: It is a narrative review that critically examines studies published since 2015 and referring to Dex’s use in ICU patients. Results: Despite the preliminary applications and the weak existing recommendation, the unique arousable sedation, in combination with mild opioid-spare analgesic effects, has been confirmed to effectively improve ICU outcomes. Moreover, the anxiolytic and sympatholytic actions have proved to sufficiently enhance sleep quality and prevent and treat ICU delirium and post-ICU syndrome, especially among elderly patients. Recently, increasing evidence advocates for promising neuro-, renal-, and cardio-protective and anti-inflammatory effects of Dex, which are attributed to autophagy and apoptosis inhibition and sympatholytic and ischemia/reperfusion (I/R) injury-protective effects. Conclusions: Beyond sedation, Dex seems to present promising neuroprotective, anti-inflammatory, and immunomodulating effects.